Galecto Validates LOXL2 Targeting With Interim Myelofibrosis Phase II Success

Galecto Inc.’s GB2064 has shown positive interim efficacy in the Phase IIa MYLOX-1 trial in myelofibrosis, giving weight to the inhibition of LOXL2 as an effective therapeutic strategy for the disease despite the target having little pipeline activity.

MYLOX-1 trial is evaluating twice-daily 1000mg doses of GB2064 in 21 myelofibrosis patients who are ineligible, refractory to or intolerant of treatment with a Janus kinase (JAK) inhibitor for nine months